A gestational carrier is a woman who bears a genetically unrelated child for another individual or couple (the intended parent[s]), usually through IVF, an assisted reproductive technology (ART) procedure involving the fertilization of oocytes outside the body and transferring the resulting embryo(s) into a woman's uterus (1) . The first reported successful pregnancy using a gestational carrier was in 1985 and has enabled those who cannot carry a pregnancy to have genetically related children (2) . Since then, there has been growing interest in this form of ART. Little is known about the use of gestational carriers in the United States, the patients opting for gestational surrogacy, and the perinatal outcomes of these pregnancies compared with other ART cycles. Studies examining gestational carriers have been limited by small sample sizes or lack of appropriate comparison groups or have been conducted outside the United States (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .
Information on success rates and pregnancy outcomes of ART cycles using gestational carriers can help both intended parents and gestational carriers make informed decisions. Additionally, identifying current national estimates and trends for the use of gestational carriers can help inform policy makers in the realm of increasingly complex legal issues surrounding gestational surrogacy (18) . The objectives of this study were to evaluate trends in ART cycles using a gestational carrier during 1999-2013 and to determine patient characteristics, ART treatment factors, and reproductive outcomes of gestational carrier cycles compared with cycles not using a gestational carrier.
MATERIALS AND METHODS
We used data from the Centers for Disease Control and Prevention's (CDC) National ART Surveillance System (NASS). All U.S. fertility clinics performing ART are required to report annual data on all ART procedures to the CDC (19) . The CDC estimates that NASS captures information on over 95% of all ART procedures performed in the United States (20) . Typically, less than 5% of data have been shown to be inaccurately collected or entered according to the annual validation of 7%-10% of clinics (20) . NASS collects cycle-specific information, and patients are not linked across multiple cycles. The unit of analysis for the current study was an ART cycle.
A gestational carrier was defined as a woman who gestates an embryo that did not develop from her oocyte, with the expectation of returning the infant to its intended parent(s). An intended parent was defined as the individual who was contracting with the gestational carrier and planning to be the social and legal parent of the child and may or may not be genetically related to the child (1).
We included all IVF cycles initiated between January 1, 1999, and December 31, 2013, where at least one embryo was transferred. We excluded ART cycles that were performed only for research purposes or for banking (ART cycles that are performed with the intention to freeze eggs or embryos for later use). Finally, cycles that had missing information on the above exclusion criteria were also excluded.
To explore trends in the use of gestational carriers, the number and percent of all IVF cycles using gestational carriers that resulted in transfer were plotted against the study year. The number and percent of all initiated cycles using gestational carriers regardless of whether they proceeded to ET were also plotted. To examine whether trends were a result of changes in the number of clinics performing gestational carrier cycles over time, the number and percent of clinics among all reporting clinics performing one or more gestational carrier cycles were plotted against study year. Given that many countries restrict gestational surrogacy (21), we examined trends in gestational carrier cycles among patients who were not residents of the United States, but using U.S. ART clinics, by restricting the study population to gestational carrier cycles and calculating the percent of these cycles with the intended parent reported to be a non-U.S. resident. Trends among non-U.S. residents were tested for two different periods, 1999-2005 and 2006-2013, owing to a change in trend in 2005. Statistically significant trends were determined using the Poisson regression.
We restricted all further analysis to the most recent years of data available, 2009-2013, to account for ART practice trends. We compared patient demographic characteristics and ART treatment factors for gestational carrier cycles and cycles not using a gestational carrier (nongestational carrier cycles). Infertility diagnoses were not mutually exclusive. Additionally, for infertility diagnosis designated as ''other,'' we examined free text entries for gestational carrier cycles and categorized them into non-mutually exclusive groups.
For nongestational carrier cycles, the patient was defined by reporting clinics as the woman undergoing the IVF cycle. For gestational carrier cycles, clinics defined the intended parent as the patient. However, in cases of male-male couples or single males using gestational carriers, clinics defined the gestational carrier as the patient and demographic information reported pertained to the carrier.
ART treatment factors included fresh versus frozen/ thawed ET, donor versus nondonor oocytes, assisted hatching, intracytoplasmic sperm injection, preimplantation genetic diagnosis, stage of ET (day 2/3 or day 5/6 typically corresponding to cleavage-or blastocyst-stage embryos, respectively, or other), number of embryos transferred, elective single ET (the transfer of only one embryo when more than one embryo is available), and number of supernumerary embryos cryopreserved. Donor oocytes were retrieved from a donor and not derived from the gestational carrier or the intended parent. Nondonor oocytes were retrieved from the intended parent. The amount of missing data was less than 1% for all variables except for gestational carrier age (34.2%), donor age (56.2%), race/ethnicity (35.4%), U.S. residency status (2.7%), and the use of elective single ET (6.5%).
We compared the distribution of demographic characteristics and ART treatment factors between gestational carrier and nongestational carrier cycles using two-tailed c 2 tests with a significance level of P< .05. We assessed the rates of the following reproductive outcomes among gestational carrier and nongestational carrier cycles: among all ET procedures we calculated implantation (the maximum number of fetal heartbeats seen on ultrasound or infants born, whichever is greater, divided by the number of embryos transferred, multiplied by 100), clinical intrauterine pregnancy, and live-birth rates; among all clinical pregnancies we calculated miscarriage rates; and among all live births, we calculated multiple live-birth, preterm delivery, and low birth weight rates. We used log-binomial regression models with generalized estimating equations for correlated outcomes within clinics to calculate unadjusted and adjusted risk ratios (aRRs) and 95% confidence intervals (CIs) for the association between reproductive outcomes and use of a gestational carrier. All models were restricted to fresh cycles because many ART treatment variables that are associated with outcomes were not available for frozen cycles (e.g., day of embryo transfer). Because ART outcomes are improved with the use of donor oocytes (22, 23) , we stratified our analysis by nondonor and donor oocyte cycles. Analysis of preterm delivery and low birthweight were also stratified by plurality. Data were analyzed using SAS 9.3. This research was approved by the Institutional Review Board at CDC.
RESULTS
A total of 2,071,984 ART cycles were performed between 1999 and 2013. After applying our exclusion criteria, there were 1,664,844 cycles, of which 30,927 (1.9%) used a gestational carrier. Gestational carrier cycles resulted in 13,380 deliveries, of which 8,581 (64%) were singleton, 4,566 (34%) were twins, and 233 (2%) were triplet or greater, resulting in 18,400 infants, with 9,819 of these infants (53.4%) from multiple gestations. While gestational carrier cycles that resulted in ET in the United States increased from 727 (1.0%) in 1999 to 3,432 (2.5%) in 2013 (P for trend < .001; Fig. 1 ), there was an apparent decrease in 2007, followed by an increase thereafter. A similar increase was seen among all initiated gestational carrier cycles (Supplemental Fig. 1 ). The number of clinics performing one or more gestational carrier cycles among all reporting clinics in the United States increased from 167 (45.1%) in 1999 to 324 (69.4%) in 2013 (P for trend < .001, Supplemental All further analyses were restricted to cycles performed during 2009-2013 (n ¼ 648,457). During this time, there were 14,682 (2.3%) gestational carrier cycles (Table 1) . Compared with nongestational carrier cycles, a greater proportion of intended parents in gestational carrier cycles were 44 years or older (23.5% vs. 6.7%). In contrast, the majority of gestational carriers were younger than 35 years. Among gestational carrier cycles, intended parents were more likely to be non-U.S. residents compared with patients from nongestational carrier cycles (15.7% vs. 1.8%). Gestational carrier cycles also had a higher proportion with two or more prior ART cycles, prior spontaneous abortions, pregnancies, and live births among intended parents compared with nongestational carrier cycles.
Infertility diagnosis varied between gestational and nongestational carrier cycles. Close to half (46.6%) of gestational carrier cycles had ''other'' reported for infertility diagnosis. However, of these 6,842 cycles, only 701 (10.3%) had a free text diagnosis entered, with most (n ¼ 359, 47.3%) only noting the use of a gestational carrier, 11.6% reporting other nonspecific reasons (i.e., family balancing, previous failed ART cycles), 10.5% reporting male same-sex couples or absence of a female partner, 9.5% reporting advanced maternal age, 9.4% reporting medical conditions that make pregnancy unsafe (i.e., kidney disease, cardiac disease), 6.3% reporting reasons compatible with uterine factor infertility (i.e., hysterectomy, Asherman's syndrome), 2.9% reporting recurrent pregnancy loss, 1.7% reporting a history of pregnancy complications (i.e., HELLP syndrome Q2 ), and 0.8% reporting genetic issues. Diminished ovarian reserve (31.5%) and uterine factor infertility (26.6%) were the second most common infertility diagnoses reported among gestational carrier cycles. The most common infertility diagnoses reported among nongestational carrier cycles were male factor (35.4%) and diminished ovarian reserve (27.7%).
Gestational carrier cycles had a higher proportion of frozen/thawed cycles compared with nongestational carrier cycles (48.7% vs. 29.9%). More than half (50.2%) of gestational carrier cycles used donor oocytes, compared with only 12.4% among nongestational carrier cycles. The use of preimplantation genetic diagnosis was higher among gestational carrier cycles compared with nongestational carrier cycles (11.5% vs. 4.2%). Additionally, day 5/6 ETs were most common among gestational carrier cycles (62.8%), while 237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295   296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354 day 2/3 ETs were most common among nongestational carrier cycles (50.7%). The transfer of two embryos was also more common among gestational carrier cycles than among nongestational carrier cycles (60.4% vs. 54.6%), and a higher percentage of gestational carrier cycles had six or more embryos cryopreserved (11.1% vs. 7.3%). Among cycles using fresh, nondonor oocytes, gestational carrier cycles had higher rates of the following reproductive outcomes compared with nongestational carrier cycles ( Table 2) : implantation (aRR, 1.22; 95% CI, 1.17-1.26), clinical pregnancy (aRR, 1.14; 95% CI, 1.10-1.19), live birth (aRR, 1.17; 95% CI, 1.12-1.21), and preterm delivery (aRR, 1.14; 95% CI, 1.05-1.23). When the risk for preterm delivery was stratified by plurality, multiple births accounted for the increased risk of preterm delivery (singletons: aRR, 1.01; 95% CI, 0.87-1.18; multiples: aRR, 1.12; 95% CI, 1.05-1.20). There was no difference in the risk of miscarriage (aRR, 0.99; 95% CI, 0.90-1.09), multiple live birth (aRR, 1.07; 95% CI, 1.00-1.15), or low birth weight (aRR, 0.93; 95% CI, 0.85-1.01). When the risk for low birth weight was stratified by plurality, however, gestational carrier cycles conferred a protective effect among singleton births but not among multiple births (singletons: aRR, 0.71; 95% CI, 0.57-0.88; multiples: aRR, 0.93; 95% CI, 0.87-1.00).
Among cycles using fresh, donor oocytes (Table 2) , adjusted analyses similarly demonstrated higher rates of reproductive outcomes among gestational carrier cycles compared with nongestational carrier cycles as seen among fresh, nondonor cycles; however, there was no difference for the risk of preterm delivery (aRR, 0.96; 95% CI, 0.89-1.02), although stratification by plurality suggests a lower risk for preterm delivery when using gestational carriers among singleton deliveries (aRR, 0.84; 95% CI, 0.71-0.98) and, to a lesser degree, multiple deliveries (aRR, 0.91; 95% CI, 0.86-0.97). Additionally, among live births, the risk for multiple birth was higher (aRR, 1.13; 95% CI, 1.08-1.19), and among pregnancies, the risk for miscarriage was lower (aRR, 0.87; 95% CI, 0.77-0.97) among gestational carrier cycles compared with nongestational carrier cycles. Overall, aRRs for implantation, clinical pregnancy, and live-birth rates were attenuated for cycles using fresh donor oocytes cycles versus cycles using fresh nondonor oocytes. Additionally, gestational carrier cycles using donor oocytes had a lower risk of low birth weight compared with nongestational carrier cycles (aRR, 0.89; 95% CI. 0.83-0.95) among both singleton and multiple births (singletons: aRR, 0.75; 95% CI, 0.60-0.93; multiples: aRR, 0.84; 95% CI, 0.79-0.90). Adjusted RRs were similar when adjusting for donor age (data not shown).
DISCUSSION
Our study, using national data, revealed an increase in the number of gestational carrier cycles during 1999-2013. We found that the number of IVF cycles using gestational carriers in the United States has more than quadrupled since 1999 and accounted for over 18,000 infants born. The reasons for this increase are unclear but may be due to the growing number of states with court cases that have established some legal framework for gestational surrogacy (24) , an increasing number of clinics that are performing gestational carrier cycles, and greater awareness and acceptance of the practice. The rapidly rising number of patients who are not U.S. residents using gestational carriers in the United States is also striking and may be due to the fact that the United States is one of the few industrialized countries that does not federally prohibit compensated gestational surrogacy, although regulations do vary by state (25, 26) .
We also found that, among ETs, gestational carrier cycles had higher rates of implantation, pregnancy, and live birth compared with nongestational carrier cycles; associations with gestational carrier status were slightly higher when nondonor oocytes were used even after adjusting for patient age. Higher rates of ART success associated with gestational carrier cycles in our study are likely due to several factors. Women serving as gestational carriers were younger than patients not using gestational carriers, with the majority of gestational carriers being less than 35 years old. Younger maternal age is associated with improved ART outcomes (27) (28) (29) . Additionally, the American Society for Reproductive Medicine guidelines recommend that gestational carriers have had at least one prior, full-term, uncomplicated pregnancy (30) . Demonstrating previous reproductive success may improve the chances of pregnancy and live birth in ART cycles using gestational carriers. Women who have had a successful pregnancy are also likely to be healthier and have other favorable patient characteristics, such as normal body mass index and nutritional status, that may improve reproductive outcomes compared with their infertile counterparts (31). The higher rates of implantation among gestational carrier cycles combined with the frequent transfer of two or more embryos in these cycles contribute to the higher risk detected for multiple live birth. Almost 80% of cycles involved the transfer two or more embryos, and less than 20% opted for elective single ET. Multifetal pregnancies are associated with elevated risks to mothers, including increased risk of hypertensive disorders, hemorrhage, cesarean delivery, and peripartum hysterectomy (32-34). We were unable to assess adverse maternal pregnancy outcomes among our study population because NASS does not currently collect this information.
Oocyte source also plays an important role in reproductive outcomes. The magnitude of the effect estimates for implantation, clinical pregnancy, and live birth among gestational carrier cycles compared with nongestational carrier cycles in our study was somewhat higher with nondonor oocytes, likely because donor oocytes independently improve ART outcomes (23) . A significantly higher risk of multiple births among gestational carriers, however, was detected only for cycles using donor oocytes, likely due to overall higher implantation rates among donor cycles. Additionally, sample sizes were smaller among gestational carrier cycles using nondonor oocytes than among those using donor oocytes, which may have limited our power to detect significant differences in multiple live-birth rates among nondonor cycles. The risk of preterm delivery was 14% higher among gestational carrier births using nondonor oocytes; but when using donor oocytes, the increased risk of multiple birth in gestational carrier cycles did not seem to confer an increased risk of preterm delivery and was associated with an 11% decreased risk of low birth weight compared with nongestational carrier births. The use of donor oocytes has been associated with improved rates of the birth of term, healthy weight infants (22) . Our study was subject to some limitations. NASS began collecting age of gestational carriers in 2007, and this is the only demographic information that is gathered on these women. Because NASS does not routinely collect information on whether a cycle is for a male-male couple or for a single male, we were only able to identify such cycles if this was mentioned in the free text field for infertility diagnosis. Therefore, we were unable to consistently distinguish gestational carrier cycles where demographic information collected pertained to the intended parent or to the gestational carrier. As a result, our findings may underestimate the difference in reproductive outcomes between gestational carrier and nongestational carrier cycles. Additionally, we have no way of knowing whether a gestational carrier is genetically related to a patient, which could also affect ART outcomes. NASS does not currently explicitly collect information on the indication for using a gestational carrier, and almost half of all gestational carrier cycles noted ''other'' as the reason for infertility. This makes differences in reproductive outcomes difficult to interpret as outcomes would likely differ based on indications for using a gestational carrier. Accordingly, NASS plans to collect information on gestational carrier indication in the future. Finally, given our large sample size, some of the statistically significant differences detected may not be clinically relevant. However, small improvements in outcomes such as live-birth rates can be substantial to patients.
Despite these limitations, our study adds much needed information to the limited existing data on the trends and outcomes of gestational surrogacy. A recent systematic review by Soderstrom-Anttila and colleagues including 55 studies that examined the medical and psychological outcomes of gestational carriers, intended parents, and babies rated all studies assessing reproductive and perinatal outcomes as lowquality evidence. The review revealed wide variability in results, and the investigators concluded that most studies suffer from ''serious methodologic limitations,'' given the small sample sizes and lack of appropriate comparison groups in most (3) .
Although the use of gestational carriers was associated with improved implantation, pregnancy, and live-birth rates, a Models were adjusted for patient age, number of prior ART cycles, number of prior spontaneous abortions, number of prior live births, infertility diagnosis, use of assisted hatching, use of intracytoplasmic sperm injection, use of preimplantation genetic diagnosis, day of ET, number of embryos transferred, and number of embryos cryopreserved. b Calculated as the maximum of the number of fetal heartbeats or infants born divided by the number of embryos transferred, multiplied by 100. c Models were adjusted for use of assisted hatching, use of intracytoplasmic sperm injection, use of preimplantation genetic diagnosis, day of ET, number of embryos transferred, and number of embryos cryopreserved.
there were concomitant increases in the risks for multiple birth and preterm delivery. The elevated risk of multiple birth among gestational carriers can potentially be mitigated by the transfer of fewer embryos given the higher chances of ART success among these cycles. Increasing the use of elective single ET among gestational carrier cycles may decrease neonatal and maternal morbidity risk. The health and future reproductive potential of gestational carriers warrants further study to protect the well-being of these women. With the dramatic increase of gestational carrier cycles in the United States, more detailed information on gestational carrier cycles may help better understand the risks and benefits of gestational surrogacy for intended parents, babies, and gestational carriers and may help inform U.S. policy decisions.
